🇺🇸 FDA
Pipeline program

Cemiplimab

R2810-ONC-2251

Phase 3 small_molecule active

Quick answer

Cemiplimab for Cutaneous Squamous Cell Carcinoma (CSCC) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Cutaneous Squamous Cell Carcinoma (CSCC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials